What is ADCT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.19B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ADCT?

P/E (TTM) is n/a and 52-week range is $0.78 to $4.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ADCT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ADCT?

The company profile lists revenue (TTM) near $66M, net income (TTM) near -$7.98B, EPS (TTM) near -$0.73 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ADC Therapeutics SA based, and what identifiers does Chartloom list?

The company context section lists headquarters in Epalinges, Vaud, CH, 127.7M shares outstanding, ISIN CH0499880968 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

ADC Therapeutics SA

$ADCT

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 188 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Employees

188

Website

adctherapeutics.com/

IPO

2020-05-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)